vs
DONEGAL GROUP INC（DGICA）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
DONEGAL GROUP INC的季度营收约是Ultragenyx Pharmaceutical Inc.的1.1倍（$236.0M vs $207.3M），DONEGAL GROUP INC净利率更高（4.9% vs -62.0%，领先66.9%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs -3.7%），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs -2.2%）
多尼戈尔集团是一家美国地区性保险控股企业，提供个人及商业财产和意外伤害保险产品，主要服务美国中大西洋、中西部及南部地区客户，为个人、家庭及中小型企业提供定制化保障方案。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
DGICA vs RARE — 直观对比
营收规模更大
DGICA
是对方的1.1倍
$207.3M
营收增速更快
RARE
高出29.6%
-3.7%
净利率更高
DGICA
高出66.9%
-62.0%
两年增速更快
RARE
近两年复合增速
-2.2%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $236.0M | $207.3M |
| 净利润 | $11.5M | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | — | -54.7% |
| 净利率 | 4.9% | -62.0% |
| 营收同比 | -3.7% | 25.9% |
| 净利润同比 | -54.3% | 3.5% |
| 每股收益（稀释后） | — | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DGICARARE
| Q1 26 | $236.0M | — | ||
| Q4 25 | $239.8M | $207.3M | ||
| Q3 25 | $245.9M | $159.9M | ||
| Q2 25 | $247.1M | $166.5M | ||
| Q1 25 | $245.2M | $139.3M | ||
| Q4 24 | $250.0M | $164.6M | ||
| Q3 24 | $251.7M | $139.5M | ||
| Q2 24 | $246.8M | $147.0M |
净利润DGICARARE
| Q1 26 | $11.5M | — | ||
| Q4 25 | $17.2M | $-128.6M | ||
| Q3 25 | $20.1M | $-180.4M | ||
| Q2 25 | $16.9M | $-115.0M | ||
| Q1 25 | $25.2M | $-151.1M | ||
| Q4 24 | $24.0M | $-133.2M | ||
| Q3 24 | $16.8M | $-133.5M | ||
| Q2 24 | $4.2M | $-131.6M |
营业利润率DGICARARE
| Q1 26 | — | — | ||
| Q4 25 | 8.7% | -54.7% | ||
| Q3 25 | 10.2% | -106.9% | ||
| Q2 25 | 8.3% | -64.8% | ||
| Q1 25 | 12.7% | -102.6% | ||
| Q4 24 | 11.9% | -74.3% | ||
| Q3 24 | 8.1% | -94.6% | ||
| Q2 24 | 2.0% | -79.1% |
净利率DGICARARE
| Q1 26 | 4.9% | — | ||
| Q4 25 | 7.2% | -62.0% | ||
| Q3 25 | 8.2% | -112.8% | ||
| Q2 25 | 6.8% | -69.0% | ||
| Q1 25 | 10.3% | -108.5% | ||
| Q4 24 | 9.6% | -80.9% | ||
| Q3 24 | 6.7% | -95.7% | ||
| Q2 24 | 1.7% | -89.5% |
每股收益（稀释后）DGICARARE
| Q1 26 | — | — | ||
| Q4 25 | — | $-1.28 | ||
| Q3 25 | — | $-1.81 | ||
| Q2 25 | — | $-1.17 | ||
| Q1 25 | — | $-1.57 | ||
| Q4 24 | — | $-1.34 | ||
| Q3 24 | — | $-1.40 | ||
| Q2 24 | — | $-1.52 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $649.1M | $-80.0M |
| 总资产 | $2.4B | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资DGICARARE
| Q1 26 | — | — | ||
| Q4 25 | — | $421.0M | ||
| Q3 25 | — | $202.5M | ||
| Q2 25 | — | $176.3M | ||
| Q1 25 | — | $127.1M | ||
| Q4 24 | — | $174.0M | ||
| Q3 24 | — | $150.6M | ||
| Q2 24 | — | $480.7M |
股东权益DGICARARE
| Q1 26 | $649.1M | — | ||
| Q4 25 | $640.4M | $-80.0M | ||
| Q3 25 | $627.4M | $9.2M | ||
| Q2 25 | $605.7M | $151.3M | ||
| Q1 25 | $584.7M | $144.2M | ||
| Q4 24 | $545.8M | $255.0M | ||
| Q3 24 | $513.4M | $346.8M | ||
| Q2 24 | $484.1M | $432.4M |
总资产DGICARARE
| Q1 26 | $2.4B | — | ||
| Q4 25 | $2.4B | $1.5B | ||
| Q3 25 | $2.4B | $1.2B | ||
| Q2 25 | $2.4B | $1.3B | ||
| Q1 25 | $2.4B | $1.3B | ||
| Q4 24 | $2.3B | $1.5B | ||
| Q3 24 | $2.3B | $1.5B | ||
| Q2 24 | $2.3B | $1.6B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | — | $-100.8M |
| 自由现金流率自由现金流/营收 | — | -48.6% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-472.0M |
8季度趋势，按日历期对齐
经营现金流DGICARARE
| Q1 26 | — | — | ||
| Q4 25 | $70.2M | $-99.8M | ||
| Q3 25 | $22.4M | $-91.4M | ||
| Q2 25 | $12.1M | $-108.3M | ||
| Q1 25 | $25.7M | $-166.5M | ||
| Q4 24 | $67.4M | $-79.3M | ||
| Q3 24 | $12.7M | $-67.0M | ||
| Q2 24 | $21.7M | $-77.0M |
自由现金流DGICARARE
| Q1 26 | — | — | ||
| Q4 25 | — | $-100.8M | ||
| Q3 25 | — | $-92.7M | ||
| Q2 25 | — | $-110.7M | ||
| Q1 25 | — | $-167.8M | ||
| Q4 24 | — | $-79.5M | ||
| Q3 24 | — | $-68.6M | ||
| Q2 24 | — | $-79.0M |
自由现金流率DGICARARE
| Q1 26 | — | — | ||
| Q4 25 | — | -48.6% | ||
| Q3 25 | — | -58.0% | ||
| Q2 25 | — | -66.5% | ||
| Q1 25 | — | -120.5% | ||
| Q4 24 | — | -48.3% | ||
| Q3 24 | — | -49.2% | ||
| Q2 24 | — | -53.7% |
资本支出强度DGICARARE
| Q1 26 | — | — | ||
| Q4 25 | — | 0.5% | ||
| Q3 25 | — | 0.8% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 1.0% | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | 1.2% | ||
| Q2 24 | — | 1.4% |
现金转化率DGICARARE
| Q1 26 | — | — | ||
| Q4 25 | 4.08× | — | ||
| Q3 25 | 1.11× | — | ||
| Q2 25 | 0.72× | — | ||
| Q1 25 | 1.02× | — | ||
| Q4 24 | 2.81× | — | ||
| Q3 24 | 0.76× | — | ||
| Q2 24 | 5.22× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DGICA
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
